Look for Drugs and Conditions

Reference pic

Covaxin's efficacy is 77·8%: Lancet study

DTMT Network

A study published in the Lancet Journal has revealed that Covaxin, India's home-grown COVID vaccine, has a 77.8% efficacy against the COVID-19 virus.

The findings of the study, which was conducted in 25 hospitals across the country with 25,000 volunteers as a part of phase 3 clinical trial, revealed that 24 of the vaccinated participants tested positive for COVID in RT-PCR tests 14 days after receiving a second dose of vaccine.

The study found that 106 people in the placebo group tested positive for COVID in an RT-PCR test at the same time, thus the infection rate among vaccinated participants was 0.3%, while it was 1.2% among unvaccinated participants, the paper revealed.

The vaccine had showed an estimated efficacy of 77·8%, the researchers of the study noted in the paper.

They also stated that the vaccine was well tolerated by the participants and that no serious adverse effects were found.

They concluded that the vaccine was highly effective against laboratory-confirmed symptomatic COVID-19 disease in adults and was well tolerated, with no safety concerns raised in this interim analysis.


0 Comments
Be first to post your comments

Post your comment

Related Articles

Ad 5